CBB, I don't think the issue is that BP's are not interested in Vascepa, per se.
The issue is a business one. Currently too many headwinds and too much risk. The U.S. market is effectively lost until something else happens, and the three biggest markets in the EU currently will not approve reimbursement for V. A BP likely doesn't want to take the risk that approvals never happen. So everyone essentially waits until those approvals come through. That's my guess, anyway.
There's also the issue that not everyone within the science and medical fields agree on the efficacy of EPA. And if the Chief Medical Officer at a given BP is in the Nissen camp, then we are SOL.
None of this is insurmountable. It's just going to take more time to shore up some of these issues, and lower the risk on Amarin as an acquisition candidate.
News 
Market Data 
Discover 
AI
